Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
4,581
5,773
6,463
6,434
5,356
4,260
Croissance des revenus (H/H)
-28.99%
-11%
0%
20%
26%
-8%
Coût des ventes
2,626
2,864
2,843
2,866
2,186
1,552
Bénéfice brut
1,955
2,908
3,619
3,567
3,170
2,708
Vente, Général et Administration
984
1,386
1,744
1,854
1,925
2,021
Recherche et développement
223
232
254
226
208
--
Frais d'exploitation
1,090
1,555
1,981
2,145
2,192
1,951
Autres revenus (charges) non opérationnels
--
--
--
--
--
--
Bénéfice avant impôts
807
1,281
1,583
1,399
948
725
Charge d'impôt sur le revenu
139
205
254
209
160
114
Bénéfice net
658
1,061
1,318
1,122
785
611
Croissance du bénéfice net
-52%
-20%
17%
43%
28%
-46%
Actions en circulation (diluées)
2,947.77
2,963.12
2,978.99
2,985.38
3,031.54
3,041.97
Variation des actions (H-H)
-1%
-1%
0%
-2%
0%
0%
EPS (dilué)
0.22
0.35
0.44
0.37
0.25
0.2
Croissance du EPS
-51%
-19%
18%
45%
28.99%
-46%
Flux de trésorerie libre
-132
-49
221
315
307
183
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
42.67%
50.37%
55.99%
55.43%
59.18%
63.56%
Marge opérationnelle
18.88%
23.41%
25.34%
22.08%
18.24%
17.74%
Marge bénéficiaire
14.36%
18.37%
20.39%
17.43%
14.65%
14.34%
Marge du flux de trésorerie libre
-2.88%
-0.84%
3.41%
4.89%
5.73%
4.29%
EBITDA
956
1,807
2,043
1,791
1,365
1,073
Marge EBITDA
20.86%
31.3%
31.61%
27.83%
25.48%
25.18%
D&A pour le résultat opérationnel
91
455
405
370
388
317
EBIT
865
1,352
1,638
1,421
977
756
Marge EBIT
18.88%
23.41%
25.34%
22.08%
18.24%
17.74%
Taux d'imposition effectif
17.22%
16%
16.04%
14.93%
16.87%
15.72%
Statistiques clés
Clôture préc.
$0.4026
Prix d'ouverture
$0.4025
Plage de la journée
$0.4025 - $0.4025
Plage de 52 semaines
$0.4025 - $0.6987
Volume
700
Volume moyen
0
BPA (TTM)
0.03
Rendement en dividend
--
Capitalisation boursière
$1.1B
Qu’est-ce que SSY GROUP LIMITED ?
SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 5,700 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.